BCRX BioCryst Pharmaceuticals, Inc.
Stock · NasdaqGS · United States · Healthcare · US09058V1035
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by BioCryst Pharmaceuticals, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price
7.69 USD
+0.79%
52-week range
6.23 – 11.22
Dividend yield—
Market cap2.0B
NowoTrade score
60 Grade A
Price history
Daily prices in USD.
Updated 08 Nov 2026 14:54. Information, not advice.
Results
Next results
25 Feb 2027
in 109 days · 08:00 · estimate 0.10
Last results
0.27 vs 0.12 estimated
04 Nov 2026 · Beat +131.1%
Beat the estimate
9 of 12
2 missed · 1 in line · 6 beats in a row
Average surprise
+45.3%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 08:00 | 0.10 | — | — | Upcoming |
| 04 Nov 2026 07:00 | 0.12 | 0.27 | +131.1% | Beat |
| 05 Aug 2026 07:00 | 0.24 | 0.35 | +49.4% | Beat |
| 06 May 2026 07:00 | 0.11 | 0.14 | +27.7% | Beat |
| 26 Feb 2026 07:00 | 0.07 | 0.21 | +197.6% | Beat |
| 03 Nov 2025 07:00 | 0.07 | 0.16 | +125.3% | Beat |
| 04 Aug 2025 07:00 | 0.03 | 0.04 | +47.1% | Beat |
| 05 May 2025 07:00 | -0.05 | — | +100.0% | — |
| 24 Feb 2025 07:00 | -0.06 | -0.13 | -115.3% | Miss |
| 04 Nov 2024 07:00 | -0.08 | -0.07 | +17.4% | Beat |
| 05 Aug 2024 07:00 | -0.16 | -0.06 | +63.3% | Beat |
| 06 May 2024 07:00 | -0.23 | -0.17 | +26.0% | Beat |
| 26 Feb 2024 07:00 | -0.22 | -0.28 | -25.6% | Miss |
| 02 Nov 2023 07:00 | -0.19 | -0.19 | 0.0% | In line |
| 03 Aug 2023 07:00 | -0.21 | -0.24 | -12.3% | Miss |
| 03 May 2023 07:00 | -0.29 | -0.28 | +2.0% | Beat |
| 21 Feb 2023 07:00 | -0.20 | -0.38 | -90.6% | Miss |
| 01 Nov 2022 07:00 | -0.26 | -0.23 | +13.1% | Beat |
| 04 Aug 2022 07:00 | -0.35 | -0.32 | +8.2% | Beat |
| 05 May 2022 07:00 | -0.40 | -0.40 | +0.4% | In line |
| 23 Feb 2022 07:00 | -0.29 | -0.40 | -38.2% | Miss |
| 03 Nov 2021 07:00 | -0.29 | -0.33 | -13.0% | Miss |
| 05 Aug 2021 07:00 | -0.25 | -0.24 | +3.1% | Beat |
| 06 May 2021 07:00 | -0.27 | -0.36 | -35.8% | Miss |
| 25 Feb 2021 07:00 | -0.24 | -0.34 | -42.6% | Miss |
| 05 Nov 2020 07:00 | -0.26 | -0.26 | -1.1% | Miss |
| 06 Aug 2020 07:00 | -0.25 | -0.24 | +4.6% | Beat |
| 06 May 2020 08:00 | -0.24 | -0.24 | +0.6% | In line |
| 05 Mar 2020 07:00 | -0.27 | -0.02 | +92.5% | Beat |
| 06 Nov 2019 07:00 | -0.31 | -0.34 | -8.1% | Miss |
| 06 Aug 2019 07:00 | -0.32 | -0.34 | -7.1% | Miss |
| 08 May 2019 07:00 | -0.28 | -0.28 | -1.8% | Miss |
| 04 Mar 2019 07:00 | -0.24 | -0.25 | -2.8% | Miss |
| 06 Nov 2018 07:00 | -0.26 | -0.28 | -7.9% | Miss |
| 07 Aug 2018 06:00 | -0.24 | -0.19 | +21.2% | Beat |
| 08 May 2018 06:00 | -0.19 | -0.26 | -35.1% | Miss |
| 27 Feb 2018 08:00 | -0.16 | -0.20 | -26.5% | Miss |
| 07 Nov 2017 06:00 | -0.18 | -0.18 | +2.4% | Beat |
| 07 Aug 2017 06:00 | -0.19 | -0.21 | -10.6% | Miss |
| 04 May 2017 06:00 | -0.19 | -0.19 | -2.1% | Miss |
| 27 Feb 2017 06:00 | -0.24 | -0.06 | +74.8% | Beat |
| 07 Nov 2016 06:00 | -0.26 | -0.16 | +37.8% | Beat |
| 04 Aug 2016 06:00 | -0.26 | -0.22 | +15.3% | Beat |
| 05 May 2016 06:00 | -0.23 | -0.31 | -34.3% | Miss |
| 23 Feb 2016 06:00 | -0.25 | -0.25 | +0.7% | In line |
| 05 Nov 2015 06:00 | -0.20 | -0.20 | +1.2% | Beat |
| 07 Aug 2015 06:00 | -0.26 | 0.06 | +122.9% | Beat |
| 08 May 2015 06:00 | -0.24 | -0.21 | +12.0% | Beat |
| 18 Feb 2015 06:00 | -0.20 | -0.16 | +20.0% | Beat |
| 06 Nov 2014 06:00 | -0.20 | -0.12 | +41.0% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 874.8M | +94.1% | 263.9M | 30.2% | 1.21 | +381.4% | 344.9M |
| 2024 | 450.7M | +36.0% | -88.9M | -19.7% | -0.43 | +63.6% | -53.1M |
| 2023 | 331.4M | +22.4% | -226.5M | -68.4% | -1.18 | +11.3% | -97.3M |
| 2022 | 270.8M | — | -247.1M | -91.2% | -1.33 | — | -163.2M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 31 Aug 2022 | 13.89 | 14.18 | 13.77 | 13.90 | +0.51% | 1,732,100 | |
| 30 Aug 2022 | 14.00 | 14.22 | 13.72 | 13.83 | -0.86% | 1,443,500 | |
| 29 Aug 2022 | 14.01 | 14.43 | 13.85 | 13.95 | -2.17% | 2,058,000 | |
| 26 Aug 2022 | 14.91 | 15.00 | 14.23 | 14.26 | -3.58% | 1,967,700 | |
| 25 Aug 2022 | 14.99 | 15.11 | 14.68 | 14.79 | -0.14% | 1,304,400 | |
| 24 Aug 2022 | 14.31 | 15.12 | 14.30 | 14.81 | +2.49% | 2,234,500 | |
| 23 Aug 2022 | 14.04 | 14.65 | 13.93 | 14.45 | +3.36% | 1,968,000 | |
| 22 Aug 2022 | 13.98 | 14.62 | 13.90 | 13.98 | -1.06% | 1,864,100 | |
| 19 Aug 2022 | 14.05 | 14.23 | 13.90 | 14.13 | -1.40% | 1,843,800 | |
| 18 Aug 2022 | 14.34 | 14.39 | 14.11 | 14.33 | +0.56% | 2,109,000 | |
| 17 Aug 2022 | 14.59 | 14.68 | 14.25 | 14.25 | -2.60% | 2,152,200 | |
| 16 Aug 2022 | 14.78 | 14.87 | 14.52 | 14.63 | -1.22% | 1,965,400 | |
| 15 Aug 2022 | 14.57 | 14.93 | 14.50 | 14.81 | +1.16% | 2,346,000 | |
| 12 Aug 2022 | 14.60 | 14.86 | 14.44 | 14.64 | +1.88% | 2,788,800 | |
| 11 Aug 2022 | 14.79 | 14.97 | 14.22 | 14.37 | -2.64% | 3,294,800 | |
| 10 Aug 2022 | 14.69 | 14.89 | 14.53 | 14.76 | +2.15% | 2,007,200 | |
| 09 Aug 2022 | 14.10 | 14.71 | 13.79 | 14.45 | +1.69% | 3,504,600 | |
| 08 Aug 2022 | 13.97 | 15.43 | 13.90 | 14.21 | +1.14% | 4,674,500 | |
| 05 Aug 2022 | 12.93 | 14.32 | 12.88 | 14.05 | +2.26% | 6,071,500 | |
| 04 Aug 2022 | 12.71 | 14.19 | 12.35 | 13.74 | +23.23% | 11,758,000 | |
| 03 Aug 2022 | 11.29 | 11.75 | 11.02 | 11.15 | +0.27% | 3,178,700 | |
| 02 Aug 2022 | 10.78 | 11.15 | 10.70 | 11.12 | +2.58% | 1,490,900 | |
| 01 Aug 2022 | 10.91 | 11.20 | 10.78 | 10.84 | -1.63% | 1,838,600 | |
| 29 Jul 2022 | 10.93 | 11.07 | 10.65 | 11.02 | +0.18% | 1,837,600 | |
| 28 Jul 2022 | 11.02 | 11.09 | 10.64 | 11.00 | -0.45% | 1,536,900 |
Page 43 of 51
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- BioCryst Pharmaceuticals (BCRX) Raised Its Outlook, Is It Still Below Fair Value? (opens in a new tab) Simply Wall St. · 07 Nov 2026 07:11
- BioCryst Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 06 Nov 2026 04:03
- Wedbush Maintains Outperform on BioCryst Pharma, Lowers Price Target to $17 (opens in a new tab) Benzinga · 05 Nov 2026 09:40
- BioCryst Pharmaceuticals Inc (BCRX) (Q3 2026) Earnings Call Highlights: ORLADEYO Revenue Climbs ... (opens in a new tab) GuruFocus.com · 05 Nov 2026 09:07
- BioCryst to Present at Upcoming Investor Conferences (opens in a new tab) 04 Nov 2026 21:01
- BioCryst Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary (opens in a new tab) Moby · 04 Nov 2026 18:01
- BioCryst (BCRX) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 04 Nov 2026 17:30
- BioCryst Pharmaceuticals Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 04 Nov 2026 16:14
- BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 04 Nov 2026 15:34
- BioCryst: Solid Q3 Earnings, But Long-Acting HAE Data Due 2027 The Key Catalyst (opens in a new tab) SeekingAlpha · 04 Nov 2026 14:20
- BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue Estimates (opens in a new tab) Zacks · 04 Nov 2026 12:55
- BioCryst: Q3 Earnings Snapshot (opens in a new tab) Associated Press · 04 Nov 2026 12:22
- BioCryst Reports Third Quarter 2026 Financial Results (opens in a new tab) 04 Nov 2026 12:00
- BioCryst Pharma Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 04 Nov 2026 10:34
- BioCryst Pharma Raises FY2026 Sales Guidance from $690.000M-$715.000M to $715.000M-$730.000M vs $710.134M Est (opens in a new tab) Benzinga · 04 Nov 2026 08:06
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 7.63 USD
- Market cap
- 2.0B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 0.0 / 25 | — |
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 16.2 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 15.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (forward) | 8.99× | Good | 14.89× |
| Price / book | -4.95× | Weak | 3.8× |
| Price / sales | 2.06× | Fair | 3.19× |
| EV / EBITDA | 5.15× | Good | 12.61× |
| Free cash flow yield | 15.2% | Good | 2.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 78.1% | Good | 58.6% |
| Operating margin | 40.1% | Good | 7.6% |
| Net margin | -37.4% | Weak | 2.7% |
| Return on assets | 56.5% | Good | 3.5% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 47.8% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | -3.68× | Good | 0.48× |
| Net debt / EBITDA | 0.96× | Good | 1.6× |
| Interest cover | 4.32× | Fair | 2.65× |
| Current ratio | 2.71× | Good | 2.36× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow BCRX and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.